Quest Diagnostics empowers people to take action to improve health outcomes.
Company Overview

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.


Learn More

Latest News

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report second quarter 2024 financial results on Tuesday, July 23, 2024, before the...


PathAI remains an independent company, focused on developing innovative AI and digital pathology solutions SECAUCUS, N.J. and BOSTON, June 11, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a...


Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer...

All Releases


Quest Blog - Empowering better health with diagnostic insights.
Media Coverage
Dermatology Times
Quest Diagnostics on Tuesday announced a new tool available to dermatologists for making treatment decisions for patients with melanoma. The gene expression test, MelaNodal Predict, is based on technology developed by the oncology biotechnology company SkylineDx and researchers at Mayo Clinic.
The Daytona Beach News-Journal
Years of exposure to nonstick cookware, fast-food packaging, fire-fighting gear and water-resistant household products have resulted in increased levels of PFAS, also known as "forever chemicals," in practically every American's bloodstream. Quest Diagnostics announced Monday the first "consumer-initiated, physician-ordered blood-draw test for PFAS chemicals." The test, which you order online, will be available from most of Quest's approximately 2,100 diagnostic centers in the country and will include (if desired) a separate telephone consultation with a licensed physician to go over the results and ways to reduce the exposure risk.

All Coverage

Quest Diagnostics Health Trends™

Quest Diagnostics Health Trends™ is a series of reports from Quest Diagnostics on health conditions affecting a large number of Americans. Published in peer-reviewed journals, at scientific conferences and widely as a public service, the reports are designed to inform health care professionals, patients and policymakers about the status of the nation’s health.


See All

At A Glance...

More than 6,600 patient access points, the most extensive network in the U.S., including phlebotomists in physician offices and more than 2,250 of our own patient service centers. A medical and scientific staff of more than 600 M.D.s and Ph.Ds. Logistics capabilities, that include approximately 3,750 courier vehicles and 25 aircraft that collectively make tens of thousands of stops daily.

Media Resources

Journalists may contact Quest Diagnostics by emailing